2025-01-26 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Report

**1. Performance Overview and Comparison to S&P 500 (VOO):**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines.

The cumulative return of VRTX (149.85%) significantly outperforms the S&P 500 (VOO) cumulative return (52.12%) over the analyzed period.  The difference in cumulative returns is 97.7 percentage points.  The relative divergence of 64.0% indicates that VRTX's performance is in the upper 64th percentile relative to its historical performance against the S&P 500.  This suggests a strong outperformance.


**Alpha and Beta Analysis:**

The provided alpha and beta values consistently show a beta of approximately 1.0 across the analyzed periods. This indicates that VRTX's price movements generally correlate with the overall market.  However, the consistently high alpha values (especially 75% in 2021-2023) highlight a substantial outperformance relative to the market.  Note the significant variations in CAGR and MDD (Maximum Drawdown) across different periods, indicating substantial volatility.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2020-2022  | -4.0% | 22.8% | -2.0% | 1.0 | 74.4 |
| 2021-2023  | 84.0% | 9.6% | 75.0% | 1.0 | 104.8 |
| 2022-2024  | 64.0% | 13.7% | 40.0% | 1.0 | 103.7 |
| 2023-2025  | 42.0% | 13.7% | -1.0% | 1.0 | 113.2 |


**2. Recent Price Movement:**

* **Closing Price:** $439.62
* **5-Day Moving Average:** $431.45
* **20-Day Moving Average:** $414.92
* **60-Day Moving Average:** $449.17

The closing price is slightly below the 5-day and significantly above the 20-day moving average, suggesting a recent minor pullback after a period of growth. It is also below the 60-day moving average, which could signal a potential short-term trend reversal.  The small negative daily change (-0.025%) indicates minimal price fluctuation compared to previous closing price.


**3. Technical Indicators and Expected Return:**

* **RSI (75.48):**  Indicates the stock is in overbought territory, suggesting a potential near-term correction.
* **PPO (1.27):**  A positive value suggests bullish momentum, although the high RSI warrants caution.
* **20-Day Relative Divergence (+5.5):** Shows a short-term upward trend.

The high RSI value and the slight daily price drop combined with the recent price movements relative to its moving averages suggest potential for short-term correction, although long-term outlook remains bullish. The expected return of 52.3% over the long term (2+ years) compared to the S&P 500 is quite optimistic and should be viewed with caution. This figure requires further context regarding the calculation methodology and underlying assumptions.


**4. Recent Earnings Analysis:**

The EPS figures show significant volatility. There's a notable negative EPS in August 2024, followed by positive figures in subsequent quarters.  Revenue growth has been steady, albeit with some minor fluctuation between quarters. A deeper analysis requires understanding the reasons behind these fluctuations (e.g., one-time expenses, seasonal factors, changes in product sales).

| Date       | EPS   | Revenue       |
|------------|-------|----------------|
| 2024-11-05 | 4.05  | $2.77 B        |
| 2024-08-02 | -13.92 | $2.65 B        |
| 2024-05-07 | 4.26  | $2.69 B        |
| 2023-11-07 | 4.01  | $2.48 B        |
| 2024-11-05 | 4.01  | $2.48 B        | *(Note: Duplicate entry?)*


**5. Financial Information:**

Both Revenue and Profit Margin show consistent high values and modest growth.  However, the Equity and ROE figures show greater variability.  The negative ROE in Q2 2024 requires further investigation to understand the underlying causes.


**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $2.77B | 85.84% |
| 2024-06-30 | $2.65B | 85.94% |
| 2024-03-31 | $2.69B | 87.27% |
| 2023-12-31 | $2.52B | 85.38% |
| 2023-09-30 | $2.48B | 87.17% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-09-30 | $15.63B | 6.69% |
| 2024-06-30 | $14.77B | -24.32% |
| 2024-03-31 | $18.55B | 5.93% |
| 2023-12-31 | $17.58B | 5.51% |
| 2023-09-30 | $16.51B | 6.27% |


**7. Overall Analysis:**

VRTX has demonstrated strong historical outperformance relative to the S&P 500. However, recent technical indicators suggest potential for a short-term correction due to overbought conditions.  The earnings data shows volatility, and the negative ROE in Q2 2024 warrants further investigation.  While long-term prospects appear positive given the company's focus and market position, investors should carefully consider the risks associated with the inherent volatility in the biotechnology sector and monitor key financial metrics closely. The projected long-term return should be treated with caution due to a lack of detailed information about the calculation method.  Further due diligence is necessary before making any investment decisions.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investing in the stock market involves risk, and you could lose money.  Consult a financial advisor before making any investment decisions.
